Statin treatment, phenotypic frailty and mortality among community-dwelling octogenarian men: the HBS cohort.

Show full item record



Permalink

http://hdl.handle.net/10138/321788

Citation

Luotola , K , Jyväkorpi , S , Urtamo , A , Pitkälä , K H , Kivimäki , M & Strandberg , T E 2020 , ' Statin treatment, phenotypic frailty and mortality among community-dwelling octogenarian men: the HBS cohort. ' , Age and Ageing , vol. 49 , no. 2 , pp. 258-263 . https://doi.org/10.1093/ageing/afz138

Title: Statin treatment, phenotypic frailty and mortality among community-dwelling octogenarian men: the HBS cohort.
Author: Luotola, Kari; Jyväkorpi, Satu; Urtamo, Annele; Pitkälä, Kaisu H.; Kivimäki, Mika; Strandberg, Timo E.
Contributor: University of Helsinki, HUS Heart and Lung Center
University of Helsinki, Department of General Practice and Primary Health Care
University of Helsinki, Clinicum
University of Helsinki, Department of General Practice and Primary Health Care
University of Helsinki, Clinicum
University of Helsinki, HUS Internal Medicine and Rehabilitation
Date: 2020-03
Number of pages: 6
Belongs to series: Age and Ageing
ISSN: 0002-0729
URI: http://hdl.handle.net/10138/321788
Abstract: BACKGROUND: statin treatment has increased also among people aged 80 years and over, but adverse effects potentially promoting frailty and loss of resilience are frequent concerns. METHODS: in the Helsinki Businessmen Study, men born in 1919-34 (original n = 3,490) have been followed up since the 1960s. In 2011, a random subcohort of home-living survivors (n = 525) was assessed using questionnaires and clinical (including identification of phenotypic frailty) and laboratory examinations. A 7-year mortality follow-up ensued. RESULTS: we compared 259 current statin users (median age 82 years, interquartile range 80-85 years) with 266 non-users (83; 80-86 years). Statin users had significantly more multimorbidity than non-users (prevalencies 72.1% and 50.4%, respectively, P < 0.0001) and worse glucose status than non-users (prevalencies of diabetes 19.0% and 9.4%, respectively, P = 0.0008). However, there was no difference in phenotypic frailty (10.7% versus 11.2%, P = 0.27), and statin users had higher plasma prealbumin level than non-users (mean levels 257.9 and 246.3 mg/L, respectively, P = 0.034 adjusted for age, body mass index and C-reactive protein) implying better nutritional status. Despite morbidity difference, age-adjusted 7-year mortality was not different between the two groups (98 and 103 men among users and non-users of statins, respectively, hazard ratio 0.96, 95% confidence interval 0.72-1.30). CONCLUSIONS: our study suggests that male octogenarian statin users preserved resilience and survival despite multimorbidity, and this may be associated with better nutritional status among statin users.
Subject: 3121 Internal medicine
Cholesterol
CARDIOVASCULAR DISEASE
Metabolic
nutrition
PREALBUMIN
Older people
cholesterol
cardiovascular disease
metabolic
nutrition
prealbumin
older people
OLDER-ADULTS
PRIMARY PREVENTION
TRANSTHYRETIN
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Statin_Treatment.pdf 235.5Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record